Dyne Therapeutics Places Major Public Stock Offering
Dyne Therapeutics, Inc. (Nasdaq: DYN), a company dedicated to advancing treatments for individuals with genetically driven neuromuscular diseases, has recently revealed its pricing for a substantial public offering. For this offering, the company has set the price at $8.25 per share, totaling around 24.2 million shares. This results in estimated gross proceeds of $200 million before accounting for any underwriting fees and associated costs, all being sold directly by Dyne.
Details of the Public Offering
The public offering is expected to be finalized around early July, subject to standard closing conditions. Dyne has also given the underwriters a strategic option to acquire an additional 3.6 million shares at the same offering price within a 30-day period. In managing this offering, the experienced financial institutions Morgan Stanley, Jefferies, Stifel, and Guggenheim Securities are serving as joint book-running managers, while Jones is contributing as a co-manager.
Registration and Prospectus Details
This offering is conducted in accordance with a shelf registration statement previously submitted to the Securities and Exchange Commission (SEC) and which became effective on filing. A preliminary prospectus supplement, outlining the offering’s specifics, has been filed with the SEC and is available at no cost on their website. Future interested parties can obtain further details by contacting the respective financial institutions mentioned, including their contact emails and phone numbers for inquiries.
Company Mission and Vision
Founded with a mission to significantly improve the quality of life for those affected by neuromuscular diseases, Dyne Therapeutics is at the forefront of developing innovative therapeutics. Their focus lies in targeting muscle-related conditions and those affecting the central nervous system (CNS). Current advancements include clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD), alongside promising preclinical initiatives addressing facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease.
Innovative Approaches to Treatment
Dyne's approach combines rigorous scientific research with a commitment to providing tailored solutions for muscle diseases. By leveraging groundbreaking therapies, Dyne aims to address the underlying causes of these debilitating conditions, striving not only to treat but also to enhance the functional capabilities and overall well-being of affected individuals.
Investor and Media Communications
For additional information or inquiries, investors can reach out to Mia Tobias at Dyne Therapeutics via email or phone. The company is also open for media communications through Stacy Nartker who is available for detailed discussions regarding Dyne's initiatives.
Contact Information
Investors: Mia Tobias
Email: ir@dyne-tx.com
Phone: 781-317-0353
Media: Stacy Nartker
Email: snartker@dyne-tx.com
Phone: 781-317-1938
Frequently Asked Questions
What is the purpose of Dyne's public offering?
The public offering aims to raise funds to further develop Dyne's therapeutics for neuromuscular diseases.
When will the offering take place?
The public offering is expected to close in early July, pending customary closing conditions.
Who is managing the public offering?
Major financial institutions including Morgan Stanley and Jefferies are managing the offering.
What are Dyne's main therapeutic focuses?
Dyne focuses on treatments for genetic neuromuscular diseases such as DM1 and DMD.
How can investors contact Dyne for more information?
Investors can reach out via email or phone to the investor relations contact provided in the press release.
